EP2411519 - KANAMYCIN ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF CANCER [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 27.05.2016 Database last updated on 31.08.2024 | Most recent event Tooltip | 17.08.2018 | Lapse of the patent in a contracting state New state(s): BG | published on 19.09.2018 [2018/38] | Applicant(s) | For all designated states Chomienne, Christine 1 rue Gustave Mathieu 77590 Bois le Roi / FR | For all designated states Padua, Rose Ann 18 Avenue Claude Vellefaux 75010 Paris / FR | [2015/37] |
Former [2015/30] | For all designated states Institut National de la Santé et de la Recherche Médicale 101, rue de Tolbiac 75013 Paris / FR | ||
For all designated states Université Paris Diderot - Paris 7 5, rue Thomas Mann 75205 Paris Cedex 13 / FR | |||
Former [2012/05] | For all designated states Institut National de la Santé et de la Recherche Medicale 101, rue de Tolbiac 75013 Paris / FR | ||
For all designated states Université Paris Diderot - Paris 7 5, rue Thomas Mann 75205 Paris Cedex 13 / FR | Inventor(s) | 01 /
see applicant ... | [2015/37] |
Former [2012/05] | 01 /
PADUA, Rose Ann Unité de Biologie Cellulaire - Hôpital Saint Louis - UMR-S-940 - Institut Universitaire d'Hématologie 1 avenue Claude Vellefaux F-75010 Paris / FR | ||
02 /
CHOMIENNE, Christine Unité de Biologie Cellulaire - Hôpital Saint Louis - UMR-S-940 - Institut Universitaire d'Hématologie 1 avenue Claude Vellefaux F-75010 Paris / FR | Representative(s) | Domenego, Bertrand Cabinet Lavoix 2, Place d'Estienne d'Orves 75441 Paris Cedex 09 / FR | [N/P] |
Former [2015/30] | Domenego, Bertrand Cabinet Lavoix 2, place d'Estienne d'Orves 75441 Paris Cedex 09 / FR | ||
Former [2012/05] | Domenego, Bertrand Cabinet Lavoix 2, place d'Estienne d'Orves 75441 Paris Cedex 09 / FR | Application number, filing date | 10711388.8 | 26.03.2010 | WO2010EP54039 | Priority number, date | EP20090290224 | 27.03.2009 Original published format: EP 09290224 | [2012/05] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2010109016 | Date: | 30.09.2010 | Language: | EN | [2010/39] | Type: | A1 Application with search report | No.: | EP2411519 | Date: | 01.02.2012 | Language: | EN | The application published by WIPO in one of the EPO official languages on 30.09.2010 takes the place of the publication of the European patent application. | [2012/05] | Type: | B1 Patent specification | No.: | EP2411519 | Date: | 22.07.2015 | Language: | EN | [2015/30] | Search report(s) | International search report - published on: | EP | 30.09.2010 | Classification | IPC: | C12N15/113, A61K31/7088, A61K39/39 | [2015/04] | CPC: |
C12N15/1137 (EP,US);
A61K39/39 (EP,US);
A61P31/04 (EP);
A61P35/00 (EP);
A61P35/02 (EP);
A61K2039/53 (EP,US);
|
Former IPC [2012/05] | C12N15/113, A61K31/7088 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2012/05] | Extension states | AL | Not yet paid | BA | Not yet paid | ME | Not yet paid | RS | Not yet paid | Title | German: | KANAMYCIN-ANTISENSE-NUCLEINSÄURE ZUR BEHANDLUNG VON KREBS | [2015/04] | English: | KANAMYCIN ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF CANCER | [2012/05] | French: | ACIDE NUCLÉIQUE ANTISENS DE LA KANAMYCINE POUR LE TRAITEMENT CONTRE LE CANCER | [2015/11] |
Former [2012/05] | KANAMYCIN-ANTISENSE-NUKLEINSÄURE ZUR KREBSBEHANDLUNG | ||
Former [2012/05] | ACIDE NUCLÉIQUE ANTISENS DE RÉSISTANCE À LA KANAMYCINE POUR LE TRAITEMENT D'UN CANCER | Entry into regional phase | 19.10.2011 | National basic fee paid | 19.10.2011 | Designation fee(s) paid | 19.10.2011 | Examination fee paid | Examination procedure | 19.10.2011 | Examination requested [2012/05] | 16.05.2012 | Amendment by applicant (claims and/or description) | 09.11.2012 | Despatch of a communication from the examining division (Time limit: M06) | 25.04.2013 | Reply to a communication from the examining division | 15.11.2013 | Despatch of a communication from the examining division (Time limit: M04) | 29.01.2014 | Reply to a communication from the examining division | 05.09.2014 | Despatch of a communication from the examining division (Time limit: M04) | 16.12.2014 | Reply to a communication from the examining division | 12.02.2015 | Communication of intention to grant the patent | 12.06.2015 | Fee for grant paid | 12.06.2015 | Fee for publishing/printing paid | 12.06.2015 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 09.11.2012 | Opposition(s) | 25.04.2016 | No opposition filed within time limit [2016/26] | Fees paid | Renewal fee | 21.03.2012 | Renewal fee patent year 03 | 21.03.2013 | Renewal fee patent year 04 | 19.09.2014 | Renewal fee patent year 05 | 30.03.2015 | Renewal fee patent year 06 | Penalty fee | Additional fee for renewal fee | 31.03.2014 | 05   M06   Fee paid on   19.09.2014 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 26.03.2010 | AT | 22.07.2015 | BE | 22.07.2015 | BG | 22.07.2015 | CY | 22.07.2015 | CZ | 22.07.2015 | DK | 22.07.2015 | EE | 22.07.2015 | FI | 22.07.2015 | HR | 22.07.2015 | LT | 22.07.2015 | LV | 22.07.2015 | MC | 22.07.2015 | MK | 22.07.2015 | PL | 22.07.2015 | RO | 22.07.2015 | SE | 22.07.2015 | SI | 22.07.2015 | SK | 22.07.2015 | SM | 22.07.2015 | TR | 22.07.2015 | NO | 22.10.2015 | GR | 23.10.2015 | IS | 22.11.2015 | PT | 23.11.2015 | IE | 26.03.2016 | LU | 26.03.2016 | MT | 31.03.2016 | [2018/38] |
Former [2018/31] | HU | 26.03.2010 | |
AT | 22.07.2015 | ||
BE | 22.07.2015 | ||
CY | 22.07.2015 | ||
CZ | 22.07.2015 | ||
DK | 22.07.2015 | ||
EE | 22.07.2015 | ||
FI | 22.07.2015 | ||
HR | 22.07.2015 | ||
LT | 22.07.2015 | ||
LV | 22.07.2015 | ||
MC | 22.07.2015 | ||
MK | 22.07.2015 | ||
PL | 22.07.2015 | ||
RO | 22.07.2015 | ||
SE | 22.07.2015 | ||
SI | 22.07.2015 | ||
SK | 22.07.2015 | ||
SM | 22.07.2015 | ||
TR | 22.07.2015 | ||
NO | 22.10.2015 | ||
GR | 23.10.2015 | ||
IS | 22.11.2015 | ||
PT | 23.11.2015 | ||
IE | 26.03.2016 | ||
LU | 26.03.2016 | ||
MT | 31.03.2016 | ||
Former [2018/29] | HU | 26.03.2010 | |
AT | 22.07.2015 | ||
BE | 22.07.2015 | ||
CY | 22.07.2015 | ||
CZ | 22.07.2015 | ||
DK | 22.07.2015 | ||
EE | 22.07.2015 | ||
FI | 22.07.2015 | ||
HR | 22.07.2015 | ||
LT | 22.07.2015 | ||
LV | 22.07.2015 | ||
MC | 22.07.2015 | ||
MK | 22.07.2015 | ||
MT | 22.07.2015 | ||
PL | 22.07.2015 | ||
RO | 22.07.2015 | ||
SE | 22.07.2015 | ||
SI | 22.07.2015 | ||
SK | 22.07.2015 | ||
SM | 22.07.2015 | ||
TR | 22.07.2015 | ||
NO | 22.10.2015 | ||
GR | 23.10.2015 | ||
IS | 22.11.2015 | ||
PT | 23.11.2015 | ||
IE | 26.03.2016 | ||
LU | 26.03.2016 | ||
Former [2018/28] | HU | 26.03.2010 | |
AT | 22.07.2015 | ||
BE | 22.07.2015 | ||
CY | 22.07.2015 | ||
CZ | 22.07.2015 | ||
DK | 22.07.2015 | ||
EE | 22.07.2015 | ||
FI | 22.07.2015 | ||
HR | 22.07.2015 | ||
LT | 22.07.2015 | ||
LV | 22.07.2015 | ||
MC | 22.07.2015 | ||
MK | 22.07.2015 | ||
MT | 22.07.2015 | ||
PL | 22.07.2015 | ||
RO | 22.07.2015 | ||
SE | 22.07.2015 | ||
SI | 22.07.2015 | ||
SK | 22.07.2015 | ||
SM | 22.07.2015 | ||
NO | 22.10.2015 | ||
GR | 23.10.2015 | ||
IS | 22.11.2015 | ||
PT | 23.11.2015 | ||
IE | 26.03.2016 | ||
LU | 26.03.2016 | ||
Former [2017/47] | AT | 22.07.2015 | |
BE | 22.07.2015 | ||
CZ | 22.07.2015 | ||
DK | 22.07.2015 | ||
EE | 22.07.2015 | ||
FI | 22.07.2015 | ||
HR | 22.07.2015 | ||
LT | 22.07.2015 | ||
LV | 22.07.2015 | ||
MC | 22.07.2015 | ||
MT | 22.07.2015 | ||
PL | 22.07.2015 | ||
RO | 22.07.2015 | ||
SE | 22.07.2015 | ||
SI | 22.07.2015 | ||
SK | 22.07.2015 | ||
NO | 22.10.2015 | ||
GR | 23.10.2015 | ||
IS | 22.11.2015 | ||
PT | 23.11.2015 | ||
IE | 26.03.2016 | ||
LU | 26.03.2016 | ||
Former [2017/07] | AT | 22.07.2015 | |
BE | 22.07.2015 | ||
CZ | 22.07.2015 | ||
DK | 22.07.2015 | ||
EE | 22.07.2015 | ||
FI | 22.07.2015 | ||
HR | 22.07.2015 | ||
LT | 22.07.2015 | ||
LV | 22.07.2015 | ||
MC | 22.07.2015 | ||
PL | 22.07.2015 | ||
RO | 22.07.2015 | ||
SE | 22.07.2015 | ||
SI | 22.07.2015 | ||
SK | 22.07.2015 | ||
NO | 22.10.2015 | ||
GR | 23.10.2015 | ||
IS | 22.11.2015 | ||
PT | 23.11.2015 | ||
IE | 26.03.2016 | ||
LU | 26.03.2016 | ||
Former [2017/03] | AT | 22.07.2015 | |
BE | 22.07.2015 | ||
CZ | 22.07.2015 | ||
DK | 22.07.2015 | ||
EE | 22.07.2015 | ||
FI | 22.07.2015 | ||
HR | 22.07.2015 | ||
LT | 22.07.2015 | ||
LV | 22.07.2015 | ||
MC | 22.07.2015 | ||
PL | 22.07.2015 | ||
RO | 22.07.2015 | ||
SE | 22.07.2015 | ||
SI | 22.07.2015 | ||
SK | 22.07.2015 | ||
NO | 22.10.2015 | ||
GR | 23.10.2015 | ||
IS | 22.11.2015 | ||
PT | 23.11.2015 | ||
LU | 26.03.2016 | ||
Former [2016/49] | AT | 22.07.2015 | |
CZ | 22.07.2015 | ||
DK | 22.07.2015 | ||
EE | 22.07.2015 | ||
FI | 22.07.2015 | ||
HR | 22.07.2015 | ||
LT | 22.07.2015 | ||
LV | 22.07.2015 | ||
MC | 22.07.2015 | ||
PL | 22.07.2015 | ||
RO | 22.07.2015 | ||
SE | 22.07.2015 | ||
SI | 22.07.2015 | ||
SK | 22.07.2015 | ||
NO | 22.10.2015 | ||
GR | 23.10.2015 | ||
IS | 22.11.2015 | ||
PT | 23.11.2015 | ||
LU | 26.03.2016 | ||
BE | 31.03.2016 | ||
Former [2016/47] | AT | 22.07.2015 | |
CZ | 22.07.2015 | ||
DK | 22.07.2015 | ||
EE | 22.07.2015 | ||
FI | 22.07.2015 | ||
HR | 22.07.2015 | ||
LT | 22.07.2015 | ||
LV | 22.07.2015 | ||
PL | 22.07.2015 | ||
RO | 22.07.2015 | ||
SE | 22.07.2015 | ||
SI | 22.07.2015 | ||
SK | 22.07.2015 | ||
NO | 22.10.2015 | ||
GR | 23.10.2015 | ||
IS | 22.11.2015 | ||
PT | 23.11.2015 | ||
LU | 26.03.2016 | ||
BE | 31.03.2016 | ||
Former [2016/36] | AT | 22.07.2015 | |
CZ | 22.07.2015 | ||
DK | 22.07.2015 | ||
EE | 22.07.2015 | ||
FI | 22.07.2015 | ||
HR | 22.07.2015 | ||
LT | 22.07.2015 | ||
LV | 22.07.2015 | ||
PL | 22.07.2015 | ||
RO | 22.07.2015 | ||
SE | 22.07.2015 | ||
SI | 22.07.2015 | ||
SK | 22.07.2015 | ||
NO | 22.10.2015 | ||
GR | 23.10.2015 | ||
IS | 22.11.2015 | ||
PT | 23.11.2015 | ||
BE | 31.03.2016 | ||
Former [2016/23] | AT | 22.07.2015 | |
CZ | 22.07.2015 | ||
DK | 22.07.2015 | ||
EE | 22.07.2015 | ||
FI | 22.07.2015 | ||
HR | 22.07.2015 | ||
LT | 22.07.2015 | ||
LV | 22.07.2015 | ||
PL | 22.07.2015 | ||
RO | 22.07.2015 | ||
SE | 22.07.2015 | ||
SK | 22.07.2015 | ||
NO | 22.10.2015 | ||
GR | 23.10.2015 | ||
IS | 22.11.2015 | ||
PT | 23.11.2015 | ||
Former [2016/22] | AT | 22.07.2015 | |
CZ | 22.07.2015 | ||
DK | 22.07.2015 | ||
EE | 22.07.2015 | ||
FI | 22.07.2015 | ||
HR | 22.07.2015 | ||
LT | 22.07.2015 | ||
LV | 22.07.2015 | ||
PL | 22.07.2015 | ||
SE | 22.07.2015 | ||
NO | 22.10.2015 | ||
GR | 23.10.2015 | ||
IS | 22.11.2015 | ||
PT | 23.11.2015 | ||
Former [2016/20] | AT | 22.07.2015 | |
DK | 22.07.2015 | ||
FI | 22.07.2015 | ||
HR | 22.07.2015 | ||
LT | 22.07.2015 | ||
LV | 22.07.2015 | ||
PL | 22.07.2015 | ||
SE | 22.07.2015 | ||
NO | 22.10.2015 | ||
GR | 23.10.2015 | ||
IS | 22.11.2015 | ||
PT | 23.11.2015 | ||
Former [2016/11] | AT | 22.07.2015 | |
FI | 22.07.2015 | ||
HR | 22.07.2015 | ||
LT | 22.07.2015 | ||
LV | 22.07.2015 | ||
PL | 22.07.2015 | ||
SE | 22.07.2015 | ||
NO | 22.10.2015 | ||
GR | 23.10.2015 | ||
IS | 22.11.2015 | ||
PT | 23.11.2015 | ||
Former [2016/10] | FI | 22.07.2015 | |
HR | 22.07.2015 | ||
LT | 22.07.2015 | ||
LV | 22.07.2015 | ||
PL | 22.07.2015 | ||
SE | 22.07.2015 | ||
NO | 22.10.2015 | ||
GR | 23.10.2015 | ||
IS | 22.11.2015 | ||
PT | 23.11.2015 | ||
Former [2016/09] | FI | 22.07.2015 | |
LT | 22.07.2015 | ||
LV | 22.07.2015 | ||
NO | 22.10.2015 | ||
GR | 23.10.2015 | ||
Former [2016/08] | LT | 22.07.2015 | |
NO | 22.10.2015 | ||
Former [2016/07] | LT | 22.07.2015 | Cited in | International search | [A]WO03090778 (INST NAT SANTE RECH MED [FR], et al) [A] 1-15 * the whole document *; | [A] - PADUA ROSE ANN ET AL, "PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia.", NATURE MEDICINE NOV 2003, (200311), vol. 9, no. 11, ISSN 1078-8956, pages 1413 - 1417, XP002541189 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1038/nm949 | [A] - MARIE ROBIN ET AL, "Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, (20051001), vol. 54, no. 10, ISSN 1432-0851, pages 933 - 943, XP019333072 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1007/s00262-005-0678-1 | Examination | EP1538206 | US2005260619 | by applicant | WO03090778 | WO9416737 | EP0187702 | WO9011092 | US5283185 | WO9115501 | WO9526356 | US5527928 | WO9318759 | WO9319768 | WO9425608 | WO9502397 | WO9100359 | WO9317706 | US4945050 | US5015580 | WO9424263 | - STEVENSON ET AL., IMMUNOLOGICAL REVIEWS, (1995), vol. 145, pages 211 - 28 | - SYRENGELAS ET AL., NATURE MEDICINE, (1996), vol. 2, pages 1038 - 41 | - RICE ET AL., NATURE REVIEWS, (2008), vol. 8, pages 108 - 20 | - PADUA ET AL., NATURE MEDICINE, (2003), vol. 9, pages 1413 - 1417 | - BROWN ET AL., PROC NATL ACAD SCI USA., (1997), vol. 94, pages 2551 - 6 | - PADUA; CHOMIENNE, DISCOVERY MEDICINE, (2004), vol. 4, pages 41 - 44 | - THE ET AL., NATURE, (1990), vol. 347, pages 558 - 61 | - DENGLER ET AL., ANTICANCER DRUGS, (1995), vol. 6, pages 522 - 32 | - GORCZYCA, CANCER RES., (1993), vol. 53, pages 1945 - 51 | - GRAHAM, B. S. ET AL., J. INFECT. DIS., (20061215), vol. 194, pages 1650 - 1660 | - MIR ET AL., PROC NATL ACAD SCI USA., (1999), vol. 96, pages 4262 - 7 | - OMIDVAR ET AL., CANCER RES, (2007), vol. 67, pages 11657 - 67 | - FURUGAKI ET AL., BLOOD, (2010), vol. 115, pages 653 - 6 | - FAN ET AL., NAT MED., (2009), vol. 15, pages 566 - 71 | - OMIDVAR ET AL., CANCER RES., (2007), vol. 67, pages 11657 - 67 |